close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ:MYNZ)

1.450 +0.180 (+14.17%)
Streaming Delayed Price Updated: 2:49 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Mainz Biomed Provides Review of 2025 Highlights
From Mainz BioMed NV
Via GlobeNewswire
News headline image
2 Small-Cap Biotechs That Could Reward Patient Investors ↗
Via MarketBeat
News headline image
Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
DoctorBox Adds Mainz Biomed’s ColoAlert(R) to Its Portfolio
DNA-based Colorectal Cancer Screening as a Home Test 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America
OncoVanguard8 is a leading service provider for innovative healthcare products for insurance companies operating in Peru, Colombia and Ecuador 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed to Attend 2025 Maxim Growth Summit
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Reports Topline Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
Study Demonstrated a Sensitivity of 100% and Specificity of 95% 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Commercial Launch of ColoAlert® in Switzerland
Company Provides Update on eAArly DETECT 2 Study 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
From Mainz BioMed NV
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies
CARE currently cooperates with 19 health insurance companies in Germany in the field of colorectal cancer screening 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
Company Advances its Progress toward FDA Premarket Approval Study for its Next Generation Colorectal Cancer Screening Product and Makes a Strategic Acquisition in the Field of Pancreatic Cancer... 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
Study is Intended to Verify Previous Discovery Results Demonstrating Sensitivity of 95% and Specificity of 98% 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants
From Mainz BioMed NV
Via GlobeNewswire
News headline image
These stocks are moving in today's pre-market session ↗
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Novavax Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Enters into Technology Partnership with EDX Medical Group
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval
From Mainz BioMed NV
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today